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Chromopeptide A, a highly cytotoxic depsipeptide from the marine sediment-derived bacterium Chromobacterium sp. HS-13-94 631. Introduction
The bacteria belonging to the genus Chromobacterium are known
to be the main source of violacein, which shows important
antitumor, antimicrobial, and antiparasitic activities1. C. violaceum
is the most studied bacterium due to the isolation of romidepsin
(2), which has been approved by the US FDA in 2009 for the
treatment of refractory cutaneous T-cell lymphoma2. Romidepsin
is a bicyclic depsipeptide composed of four amino acids (D-valine,
D-cysteine, Z-dehydrobutyrine, L-valine) and (3S, 4E)-3-hydroxy-
7-mercapto-4-heptenoic acid2. Inspired by this discovery, a series
of depsipeptides structurally related to romidepsin, such as
spiruchostatins, burkholdacs, and thailandepsins3–6, have been
isolated and characterized.
In the course of our continuing search for new bioactive
substances from marine microorganisms7–10, a bacterial strain,
HS-13-94, belonging to the genus Chromobacterium, was recently
isolated from the sediment collected from the East China Sea,
Zhejiang Province, China. A chemical investigation of the whole
culture of the bacterium HS-13-94 led to the isolation of a
depsipeptide, chromopeptide A (1), which shares a common
bicyclic framework as compound 2 but possessing an unusual
trisulﬁde bond in the molecule. This paper describes the isolation,
structural elucidation and cytotoxic activity of compound 1
(Fig. 1).2. Results and discussion
Compound 1 was isolated as a colorless block crystal. Its
molecular formula was deduced to be C24H36N4O6S3 from the
pseudo-molecular ion peak at m/z 595.1678 [MþNa]þ (cald.
595.1689) by HR-ESI-MS spectrum, indicating the presence of
nine degrees of unsaturation. The IR spectrum showed absorption
bands of amines and carbonyls at νmax 3350 and 1734 cm
1,
respectively. The 1H and 13C NMR spectra (Table 1) showed
diagnostic signals ascribable to ﬁve carbonyls (δC 171.1, 170.8,
169.7, 169.3 and 164.1) and four amide protons (δH 8.91, s; 8.16,
d, J¼4.3 Hz; 7.16, d, J¼8.3 Hz; and 7.02, d, J¼9.5 Hz), indi-
cating the peptide nature of compound 1. The presence of a tri-
substituted double bond (δC 130.5 and 130.9; δH 6.44, d, J¼7.1
Hz) and a disubstituted double bond (δC 129.9 and 131.2; δH 5.79,
m and 5.73, brd, J¼16.2 Hz) were easily recognized in the 1H and
13C NMR spectra. Five methyls, including one vinyl methyl (δH
1.61, d, J¼7.1 Hz) and four secondary methyls (δH 1.05, d,
J¼6.8 Hz; 0.99, d, J¼6.8 Hz; 0.90, d, J¼6.8 Hz; and 0.88, d,
J¼6.8 Hz), were also observed in the 1H NMR spectrum of 1.
These data account for seven of the required nine sites of
unsaturation, implying compound 1 possesses two rings.Figure 1 Structures of 1 and 2.The presence of three amino acids (one cysteine and two valines)
was established by extensive interpretation of the 2D NMR spectra of
1 (Fig. 2). Moreover, detailed analysis of the two-dimensional NMR
spectra allowed for the identiﬁcation of the other two fragments,
dehydrobutyrine and acyl-(3S, 4E)-3-hydroxy-7-mercapto-4-heptenoic
acid. All these elaborated subunits were connected mainly by HMBC
correlations of the carbonyl carbon of one amide acid residue with the
amide protons of the neighboring residue, and the carbonyl carbon
signals in each amino acid unit were deduced by their HMBC
correlations with the α or β proton of their respective amino acids
(Fig. 2), whereas the ester bond between the second valine and the
hydroxyl in acyl-heptenoic acid group were deduced from the
downﬁeld chemical shift of C-3 (δC 71.6) (Table 1).
Subtraction of the atoms present in the above elaborated
macrocyclic core from the molecular formula of 1 indicated that
only two sulﬁde atoms remain unassigned. Bearing in mind the
unsaturation degrees of 1, the two sulﬁdes have to connect with the
sulﬁde atom of a cysteine, forming a trisulﬁde bridge between the
two appendages at C(7) and the β carbon in the cysteine. As a
consequence, the planar structure of chromopeptide A was thus
constructed (Fig. 1), which was in good agreement with its
molecular composition and nine degrees of unsaturation.
To secure the assigned structure and also to determine its
absolute conﬁguration, a suitable crystal of chromopeptide A,
obtained from CHCl3/MeOH (1:1, v/v), was subjected to X-ray
diffraction analysis (Fig. 3). The X-ray result not only completely
agreed with the proposed structure but also allowed unambiguous
assignment of its absolute conﬁguration with absolute structure
parameter 0.03(7) based on the ﬁnal reﬁnement on the Mo Kα data,
and due to the existence of heavy sulfur atom in 1. Thus, the
structure of 1, including the absolute conﬁguration, was con-
ﬁdently assigned.
A systematic literature review revealed that the structure of 1
was very similar to that of FR 901228 (romidepsin, 2)11. In fact,
the main difference between them was that a disulﬁde bond in 2
was replaced by a trisulﬁde bridge linkage in 1. It is worthwhile to
note that, although the structure of 1 had been mentioned in a
previous report12, it actually describes a method for the preparation
of 2. To the best of our knowledge, this is the ﬁrst report of the full
NMR data assignment and X-ray structure of 1.
The cytotoxic activities of 1 against tumor cell lines including
HL-60 (acute promyelocytic leukemia), K-562 (chronic myelo-
genous leukemia), and Ramos (Burkitt's lymphoma) were eval-
uated by CCK-8 assay as described previously13,14. The results
showed that 1 signiﬁcantly suppressed the proliferation of HL-60,
K-562, and Ramos cells, with average IC50 values of 7.7, 7.0 and
16.5 nmol/L, respectively, which is comparable to that of 2. Since
the structure of 1 is very similar to that of 2, an HDAC (histone
deacetylase) inhibitor approved by the US FDA, we are currently
evaluating the ability of 1 to target and inhibit HDACs.3. Conclusions
In summary, chromopeptide A (1), a new depsipeptide structurally
related to the known clinically used drug romidepsin, was isolated
from a deep-sea-derived bacterium Chromobacterium sp. HS-13-
94. Chromopeptide A exhibited potent cytotoxic activities against
HL-60, K-562, and Ramos cell lines. In light of the observation
that there is structural similarity between chromopeptide A and
romidepsin, the biosynthetic pathway for chromopeptide A should
probably be the same as that of romidepsin15. However, formation
Table 1 1H (400 MHz) and 13C NMR (100 MHz) data for chromopeptide A (1) in DMSO-d6.
Fragment Position δH, mult. (J in Hz) δC, mult. Fragment Position δH, mult. (J in Hz) δC, mult.
Acyl 1 171.1, C D-Cys NH 7.02, d (9.5)
2 2.58, dd (12.9, 6.4) 39.4, CH2 α 5.19, m 49.9, CH
2.84, m β 2.82, m 47.9, CH2
3 5.53, m 71.6, CH 3.83, dd (14.8, 3.0)
4 5.73, brd (16.2) 131.2, CH CO 169.3, C
5 5.79, m 129.9, CH Dehb NH 8.91, s
6 2.55, m 29.3, CH2 α 130.5, C
7 2.96, m 40.2, CH2 β 6.44, q (7.1) 130.9, CH
3.23, m γ 1.61, d (7.1) 13.4, CH3
D-Val1 NH 8.16, d (4.3) CO 164.1, C
α 3.89, dd (5.6, 4.6) 62.1, CH L-Val2 NH 7.16, d (8.3)
β 2.19, m 29.2, CH α 4.45, dd (8.2, 4.6) 57.7, CH
γ 0.99, d (6.8) 19.7, CH3 β 2.22, m 31.5, CH
1.05, d (6.8) 19.8, CH3 γ 0.88, d (6.8) 19.5, CH3
CO 170.8, C 0.90, d (6.8) 18.7, CH3
CO 169.7, C
Figure 2 Selected key COZY and HMBC correlations of 1.
Figure 3 The X-ray crystallographic structure for 1.
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further experimental investigation is needed. Moreover, in con-
nection with the mode of action of FR 901228 (romidepsin, 2)16,
chromopeptide A may mediate antitumor activity through the same
molecular mechanism. Further studies should be conducted to both
understand its true biosynthetic pathway and to evaluate its use as
an HDAC inhibitor.4. Experimental
4.1. General procedure
Optical rotations were measured on a Perkin-Elmer polarimeter
343. UV spectrum was recorded on a Mariner System 5304
Spectrometer. IR spectrum was determined on a Nicolet 5700
FT-IR Microscope Spectrometer (FT-IR Microscope Transmis-
sion). 1H and 13C NMR spectra were acquired on a Bruker DRX-
400 spectrometer. The chemical shifts (δ) were reported in ppm,
and coupling constants (J) were given in Hz. The ESI-MS and HR-
ESI-MS data were recorded on the Bruker APEX III 7.0T
spectrometer. Macroporous resin (SP850 and HP20ss, Mitsubishi
Chemical Industries Ltd.) was used for column chromatography.
Reversed-phase HPLC was performed on an Agilent 1100 liquid
chromatography equipped with a Diode Array Detector at 210 nm.
A semi-preparative Agilent ZORBAX-XDB column [250 mm
9.4 mm, 5 μm] was employed for the puriﬁcations. Pre-coated
silica gel GF254 plates (Qing Dao Hai Yang Chemical Group Co.,Ltd., Qingdao, China) were used for analytical thin-layer chroma-
tography (TLC). All solvents used were of analytical grade
(Shanghai Chemical Reagents Co., Ltd.).
4.2. Bacterial material
The bacterial strain HS-13-94 was isolated from sediment col-
lected from the East China Sea, Zhejiang, China and deposited in
the China General Microbiological Culture Collection Center with
the accession number CGMCC No. 6247. It was initially identiﬁed
as Chromobacterium species based on its morphological charac-
ters and 16S rDNA sequence as described in previous literature17.
4.3. Fermentation and isolation
The bacterial strain was cultured on slants of agar (10 g tryptone,
5 g yeast extract, 10 g NaCl, 15 g agar per liter of tap water) at
37 1C for 3 days. The seeds from the above mature slant culture
was inoculated into 1 L Erlenmeyer ﬂask containing 200 mL
Table 2 The antiproliferative activities of chromopeptide A
(1) and romidepsin (2).
Compound IC50 (nmol/L)
HL-60 K-562 Ramos
1 7.774.0 7.071.0 16.573.5
2 3.373.2 6.770.6 11.072.8
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extract, and 10 g/L NaCl, and cultured on a rotary shaker
(250 rpm) at 30 1C for 12 h. Fermentation was performed in
50 L fermentor containing 30 L culture medium (4% glucose,
2% starch, 2% peptone, 0.5% NaH2PO4, and 0.1% valine). The
fermentor was inoculated with 3% of the seed culture and
maintained on a 100 rpm rotary shaker at 30 1C for 2 days. Upon
harvest, the ﬁltrate of 30 L of fermentation culture was fractionated
by column chromatography over the macroporous adsorbent resin
SP850 (Mitsubishi Chemical, Japan) (acetone/H2O, 0%, 25%, and
65%, v/v). The fractions with similar TLC proﬁles were combined
and separated on a column of macroporous resin HP20ss (acetone/
H2O, 25%, 40%, and 50%, v/v) to obtain three fractions. The third
fraction was extracted with EtOAc to give the crude extract, which
was further puriﬁed by HPLC (MeOH/H2O v/v¼65:35) to afford
compound 1 (tR¼13.4 min, 27 mg).
4.4. Characerizaiton of 1
Colorless crystal, [α]20D ¼84.61 (c¼0.026, EtOH); IR νmax (KBr)
cm1: 3350, 2962, 2929, 1734, 1699, 1669, 1520, 1507, 1457, 1258,
1080. 1H NMR (400 MHz, DMSO-d6) and
13C NMR (100 MHz,
DMSO-d6) spectroscopic data are shown in Table 1. HR-ESI-MS m/z
595.1678 [MþNa]þ(Calcd.for C24H36N4O6S3Na 595.1689).
4.5. Crystal data for 1
Compound 1 was crystallized from CHCl3/MeOH (v/v¼1:1) to
give colorless block. Crystal data: 2(C24H36N4O6S3) CHCl3,
M¼1260.89, trigonal, a¼14.6553(14) Å, b¼14.6553(14) Å,
c¼28.089(3) Å, α¼90.001, β¼90.001, γ¼120.001, V¼5224.6
(9) Å3, T¼133(2) K, space group P3(2), Z¼3, 13559 reﬂections
measured, 12196 independent reﬂections (Rint¼0.039). The ﬁnal
R1 values were 0.0681 (I42σ(I)). The ﬁnal wR(F
2) values were
0.1889 (I42σ(I)). The ﬁnal R1 values were 0.0740 (all data). The
ﬁnal wR(F2) values were 0.1888 (all data). The structure was
solved by direct methods (SHELXS97) and reﬁned by using full-
matrix least-squares difference Fourier techniques. All non-
hydrogen atoms were reﬁned anisotropically, and all hydrogen
atoms were placed in idealized positions and reﬁned as riding
atoms with their related isotropic parameters. Crystallographic data
(excluding structure factors) for the structure in this paper have
been deposited with the Cambridge Crystallographic Data Center
as supplementary publication No. CCDC 1019172. Copies of the
data can be obtained, free of charge, on application to CCDC, 12
Union Road, Cambridge CB2 1EZ, UK (fax: þ44 1223 336033 or
E-mail: deposit@ccdc.cam.ac.uk).
4.6. Antitumor bioassays
For cytotoxicity measurements, stock epothilonoside solutions
were prepared at 100 mg/mL in dimethyl sulfoxide and stored at
20 1C. Acute promyelocytic leukemia HL-60, chronic myelo-
genous leukemia K-562, and Burkitt's lymphoma Ramos were
obtained from the Institute of Biochemistry and Cell Biology,
Shanghai, Chinese Academy of Sciences. All cell lines were
routinely cultured in Dulbecco's modiﬁed Eagle's medium contain-
ing 10% calf serum at 37 1C for 4 h, in a humidiﬁed atmosphere of
5% CO2. The adherent cells at their logarithmic growth stage were
digested and inoculated onto a 96-well culture plate at a density of
1.0 104/well for the determination of proliferation. Test samplesranging from 0.1–100 mg/mL in 100 mL were added to cells in
triplicate wells, and incubation was continued for 72 h. Coloration
substrate from cell counting kit-8 (CCK-8, Dojindo, Kumamoto,
Japan), was added to the medium, followed by further incubation
for 3 h. Absorbance at 450 nm with a 600 nm reference was
measured. Media and dimethyl sulfoxide control wells in which
the compound was absent were included in all the experiments in
order to eliminate the inﬂuence of dimethyl sulfoxide. The
inhibitory rate of cell proliferation was calculated by the formula
(1) (where OD stands for optical density)
Growth inhibition %ð Þ ¼ ODcontrol–ODtreated½ =ODcontrol  100 ð1Þ
The cytotoxicity of compound on tumor cells was expressed as
IC50 values (the drug concentration reducing the absorbance in
treated cells by 50%, with respect to untreated cells) and was
calculated by the LOGIT method (Table 2).
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